Rosuvastatin Safety in Pregnancy

Primary Recommendation

The American College of Cardiology recommends that all statins, including rosuvastatin, are generally not recommended during pregnancy for the vast majority of women 1, 2, 3

Women planning pregnancy should stop rosuvastatin 1-2 months before attempting conception, according to the American College of Cardiology 3
Unplanned pregnancy requires immediate discontinuation of rosuvastatin upon pregnancy discovery, as recommended by the American College of Cardiology and Diabetes Care 2, 3
Sexually active women of childbearing age must use reliable contraception while on statin therapy, as advised by the American College of Cardiology 3

Historical concerns about teratogenic risk stemmed from a 2004 FDA case series, but the American College of Cardiology notes that the evidence regarding birth defects is reassuring but not definitive 3, 4
The American College of Cardiology reports that meta-analyses have not confirmed increased teratogenic risk, though study quality remains limited 3, 4

The American College of Cardiology and Diabetes Care report an increased risk of spontaneous pregnancy loss in statin-exposed women, though this may be confounded by maternal age, cardiovascular risk factors, and other medications 3, 4

The American College of Cardiology emphasizes the importance of lifestyle modifications for all pregnant women 3

The American College of Cardiology advises against continuing statins in women taking them for primary prevention, as the cardiovascular benefit during 9 months of pregnancy is negligible compared to potential fetal risks 3, 4
The American College of Cardiology recommends that sexually active women of childbearing age on statins must use reliable contraception 3

The American College of Cardiology recommends that statins are generally not recommended during pregnancy for most women, particularly those taking them for primary prevention of cardiovascular disease 5, 6
For a small subset of very high-risk pregnant patients, the benefits of statin therapy may outweigh risks in specific situations, such as women with homozygous familial hypercholesterolemia (HoFH) or established clinical atherosclerotic cardiovascular disease (ASCVD) at very high risk for heart attack or stroke 5, 6
Women taking statins for primary prevention of ASCVD should discontinue therapy at least 1 month and preferably 3 months before attempted conception, or immediately if already pregnant 5, 6
Pregnant patients managed with bile acid sequestrants should be monitored for vitamin K deficiency 5

Lipid-lowering therapy may be resumed after completion of breastfeeding, according to the American College of Cardiology 5

The American College of Cardiology recommends determining if a patient is pregnant or planning pregnancy, assessing cardiovascular risk category, and discontinuing atorvastatin immediately if necessary 5
If discontinuation is indicated, patients should be monitored for significant elevations in LDL-C and triglycerides during pregnancy, counseled on lifestyle modifications, and considered for bile acid sequestrants if absolutely necessary 5
The American College of Cardiology recommends resuming statin therapy after completion of breastfeeding 5